Online pharmacy Valisure has raised concerns about what it believes are risky levels of another probable carcinogen in valsartan, filing a citizen petition with the US Food and Drug Administration on 13 June requesting that the agency significantly lower the permitted daily exposure (PDE) limit of the residual solvent, called N-Dimethylformamide (DMF).
Further, the pharmacy wants manufacturers to recall lots of drugs where it found concerning levels of DMF impurities
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?